Table 1.
Characteristics of Patients By Clinical Trial
| Clinical trial (DISEASE) | 40101* breast cancer | 50303 non- Hodgkin’s lymphoma | 80101 gastric cancer | 80203 metastatic colorectal cancer | 80405 metastatic colon cancer | 80303 pancreatic cancer | 90401 prostate cancer | Total |
|---|---|---|---|---|---|---|---|---|
| Characteristic | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) |
| Sample size | 3314 (39.2) | 423 (5.0) | 546 (6.5) | 238 (2.8) | 2283 (27.0) | 602 (7.1) | 1050 (12.4) | 8456 |
| Trial status | Closed | Open | Closed | Closed | Closed | Closed | Closed | --- |
| Race | ||||||||
| Caucasian | 2759 (83.3) | 339 (80.1) | 403 (73.8) | 207 (87.0) | 1859 (81.4) | 529 (87.9) | 923 (87.9) | 7019 (83.0) |
| African American | 362 (10.9) | 47 (11.1) | 71 (13.0) | 27 (11.3) | 273 (12.0) | 49 (8.1) | 110 (10.5) | 939 (11.1) |
| Asian | 62 (1.9) | 14 (3.3) | 45 (8.2) | 1 (0.4) | 72 (3.2) | 10 (1.7) | 7 (0.7) | 211 (2.5) |
| Other | 36 (1.1) | 7 (1.7) | 4 (0.7) | 1 (0.4) | 25 (1.1) | 5 (0.8) | 5 (0.5) | 83 (1.0) |
| Unknown | 95 (2.9) | 16 (3.8) | 23 (4.2) | 2 (0.8) | 54 (2.4) | 9 (1.5) | 5 (0.5) | 204 (2.4) |
| Minority† | ||||||||
| White | 2759 (85.7) | 339 (83.3) | 403 (77.1) | 207 (87.7) | 1859 (83.4) | 529 (89.2) | 923 (88.3) | 7019 (85.1) |
| Nonwhite | 460 (14.3) | 68 (16.7) | 120 (22.9) | 29 (12.3) | 370 (16.6) | 64 (10.8) | 122 (11.7) | 1233 (14.9) |
| Sex | ||||||||
| Male | NA | 226 (53.4) | 371 (67.9) | 140 (58.8) | 1324 (58.0) | 329 (54.7) | 1050 (100.0) | 3440 (40.7) |
| Female | 3314 (100.0) | 197 (46.6) | 175 (32.1) | 98 (41.2) | 959 (42.0) | 273 (45.3) | NA | 5016 (59.3) |
| Age, y | ||||||||
| Median | 53 | 57.5 | 58.7 | 61.3 | 59.1 | 64.2 | 69 | 58.3 |
| Range | 22.5 – 84.7 | 18.8 – 86.6 | 23.2 – 83.1 | 22 – 84.4 | 20.8 – 89.5 | 26.3 – 88.6 | 41.7 – 93.5 | 18.8–93.5 |
| Institution | ||||||||
| CTSU | 1755 (53.0) | 186 (44.0) | 384 (70.3) | 123 (51.7) | 1553 (68.0) | 282 (46.8) | 564 (53.7) | 4847 (57.3) |
| CALGB | 1559 (47.0) | 237 (56.0) | 162 (29.7) | 115 (48.3) | 730 (32.0) | 320 (53.0) | 486 (46.3) | 3609 (42.7) |
| Consent to pharmacogenomics | 2768 (83.5) | 384 (90.8) | 416 (76.2) | 219 (92.0) | 1756 (76.9) | 475 (78.9) | 864 (82.3) | 6882 (81.4) |
* Trial 40101: patients registered before November 1, 2003 are not included in the statistical analysis, as the pharmacogenomics study was not open at that time.
† Eight thousand two hundred fifty-two patients with known racial status: white = Caucasian: nonwhite = African American, Asian, and other (Pacific Islander, Hawaiian, multirace).